ARCT

Arcturus Therape

7.65

-0.12-1.54%

Pre Market: 7.50 -0.15 -1.96%05:28 06/03 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE7.83/7.77

TODAY RANGE7.49-7.86

VOL125

MARKET CAP217.44M

52 WEEK RANGE5.85-24.17

AVG VOL (3M)469.38K

% TURNOVER1.64%

TURNOVER0

P/E (TTM)-2.7167

% RANGE4.76%

EPS(TTM)-2.8159

P/E(FORWARD)-1.9666

P/B1.136

BVPS6.73

DIVIDEND--

P/S2.650

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP200.07M

SHARES OUTSTANDING28.42M

NEXT EARNINGS08/10-08/14

FREE FLOAT26.15M

LOT SIZE1

EX-DATE11/16/2017

News

Press Releases

Financial Reports

Profile

TipRanks·05/20 04:33
Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
TipRanks·05/13 10:36
ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
TipRanks·05/11 12:03
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Arcturus Therapeutics (ARCT) and Waters (WAT)
TipRanks·05/09 01:17
Arcturus Therapeutics Signals Progress Amid Revenue Slip
TipRanks·05/08 10:48
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
TipRanks·05/08 10:41
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), Celldex (CLDX) and Collegium Pharmaceutical (COLL)
Seeking Alpha·05/08 04:32
Arcturus outlines 12-week ARCT-032 Phase II enrollment and extends cash runway beyond Q2 2028
TipRanks·05/07 21:28
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
Reuters·05/07 21:02
ARCTURUS THERAPEUTICS HOLDINGS INC - APPOINTS DENNIS MULROY AS CFO EFFECTIVE MAY 1, 2026 - SEC FILING
PUBT·05/07 20:33
Arcturus Therapeutics CFO Dennis Mulroy files initial beneficial ownership statement
Reuters·05/07 20:09
Arcturus Therapeutics Q1 revenue drops sharply, net loss widens
Seeking Alpha·05/07 20:05
Arcturus Therapeutics GAAP EPS of -$0.95 beats by $0.04, revenue of $2.06M misses by $4.81M
Dow Jones·05/07 20:01
*Arcturus Therapeutics 1Q Loss $27M >ARCT
Dow Jones·05/07 20:01
Press Release: Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress
Dow Jones·05/07 20:01
Press Release: Arcturus Therapeutics Announces -2-

Same Industry

Name/Symbol

Change%

Price

ARCT

Regeneron Pharmaceuticals

REGN

-1.08%

614.78

GRDX

BIONTECH

BNTX

-3.82%

92.28

United Therapeutics Corp.

UTHR

-0.94%

556.82

Vertex Pharmaceuticals Inc

VRTX

-2.22%

437.60

SIGA

Moderna

MRNA

-0.80%

47.19

Charles Riv Labs Intl Inc

CRL

-2.94%

176.72

MEDP

TLPH

ICON plc

ICLR

-0.36%

137.54

CBPO

IQV

MOLECULAR PARTNERS AG

MOLN

-0.76%

3.920

Gilead Sciences Inc

GILD

-2.13%

128.31

PRAH

APVO

INCY

BSTC

Kiniksa Pharmaceuticals International, plc

KNSA

-4.84%

48.38

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.